Jennifer R Bellon

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Controversies in Radiation Oncology for Early-Stage Breast Cancer
    Jennifer R Bellon
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA, USA
    Ann Surg Oncol 22:3213-8. 2015
  2. ncbi request reprint A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma
    Jennifer R Bellon
    Department of Radiation Oncology, Brigham and Women s Hospital and the Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 100:1358-64. 2004
  3. ncbi request reprint Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC)
    Jennifer R Bellon
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA, USA
    Am J Clin Oncol 27:407-10. 2004
  4. doi request reprint ACR Appropriateness Criteria® conservative surgery and radiation--stage I and II breast carcinoma: expert panel on radiation oncology: breast
    Jennifer R Bellon
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Breast J 17:448-55. 2011
  5. ncbi request reprint Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial
    Jennifer R Bellon
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 23:1934-40. 2005
  6. ncbi request reprint What extent of radiation therapy is standard?
    Jennifer R Bellon
    Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Breast 14:532-40. 2005
  7. doi request reprint The association between biological subtype and isolated regional nodal failure after breast-conserving therapy
    Jennifer Y Wo
    Harvard Radiation Oncology Program, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 77:188-96. 2010
  8. doi request reprint ACR appropriateness criteria® locally advanced breast cancer
    Shannon M Macdonald
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Breast J 17:579-85. 2011
  9. doi request reprint Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer
    Angela Katz
    Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 301, Boston, MA 02114, USA
    J Clin Oncol 26:2093-8. 2008
  10. pmc Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy
    Jona A Hattangadi-Gluth
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Int J Radiat Oncol Biol Phys 82:1185-91. 2012

Detail Information

Publications45

  1. doi request reprint Controversies in Radiation Oncology for Early-Stage Breast Cancer
    Jennifer R Bellon
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA, USA
    Ann Surg Oncol 22:3213-8. 2015
    ..Multiple trials have attempted to identify patients who can safely forego radiation and, more recently, molecular predictors of recurrence have been developed to further fine-tune this low-risk population. ..
  2. ncbi request reprint A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma
    Jennifer R Bellon
    Department of Radiation Oncology, Brigham and Women s Hospital and the Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 100:1358-64. 2004
    ..We present updated results of a prospective protocol of concurrent cyclophosphamide/methotrexate/5-fluorouracil (CMF) and reduced-dose radiotherapy, focusing on tumor control and patient tolerance...
  3. ncbi request reprint Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC)
    Jennifer R Bellon
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA, USA
    Am J Clin Oncol 27:407-10. 2004
    ..FDG-PET appears to be a useful noninvasive modality to detect IM metastases in LABC. Pathologic verification in a prospective study is necessary to confirm these findings...
  4. doi request reprint ACR Appropriateness Criteria® conservative surgery and radiation--stage I and II breast carcinoma: expert panel on radiation oncology: breast
    Jennifer R Bellon
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Breast J 17:448-55. 2011
    ..Several randomized studies are ongoing to determine the efficacy, safety, and appropriate patients for these shorter treatments...
  5. ncbi request reprint Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial
    Jennifer R Bellon
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 23:1934-40. 2005
    ..The optimal integration of chemotherapy with radiation (RT) for patients with early-stage breast cancer remains uncertain. We present the long-term results of a prospective randomized trial to address this question...
  6. ncbi request reprint What extent of radiation therapy is standard?
    Jennifer R Bellon
    Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Breast 14:532-40. 2005
    ..In addition, this review will primarily focus on results obtained from randomized clinical trials (RCTs). Finally, we acknowledge an American point of view in our discussion...
  7. doi request reprint The association between biological subtype and isolated regional nodal failure after breast-conserving therapy
    Jennifer Y Wo
    Harvard Radiation Oncology Program, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 77:188-96. 2010
    ....
  8. doi request reprint ACR appropriateness criteria® locally advanced breast cancer
    Shannon M Macdonald
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Breast J 17:579-85. 2011
    ..In those instances where evidence is either lacking or not definitive, expert opinion may be used to recommend imaging or treatment...
  9. doi request reprint Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer
    Angela Katz
    Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 301, Boston, MA 02114, USA
    J Clin Oncol 26:2093-8. 2008
    ..The purpose of this study was to define possible predictors of having four or more involved nodes to provide information for clinicians and patients making decisions about adjuvant chemotherapy and radiation...
  10. pmc Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy
    Jona A Hattangadi-Gluth
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Int J Radiat Oncol Biol Phys 82:1185-91. 2012
    ....
  11. pmc Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy
    Nils D Arvold
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02215, USA
    J Clin Oncol 29:3885-91. 2011
    ..Prior results of breast-conserving therapy (BCT) have shown substantial rates of local recurrence (LR) in young patients with breast cancer (BC)...
  12. doi request reprint Tangential radiotherapy without axillary surgery in early-stage breast cancer: results of a prospective trial
    Julia S Wong
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 72:866-70. 2008
    ....
  13. doi request reprint Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ
    Stephanie K Childs
    Harvard Radiation Oncology Program, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 85:948-52. 2013
    ..To examine the rate of local recurrence according to the margin status for patients with pure ductal carcinoma in situ (DCIS) treated by mastectomy...
  14. doi request reprint Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy
    Paul L Nguyen
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 26:2373-8. 2008
    ..To determine whether breast cancer subtype is associated with outcome after breast-conserving therapy (BCT) consisting of lumpectomy and radiation therapy...
  15. doi request reprint Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011
    Monica S Krishnan
    Harvard Radiation Oncology Program, Boston, MA, USA
    Breast Cancer Res Treat 138:205-13. 2013
    ..6 % or lymphedema risk with ALND is under 10 %. Patients eligible for Z0011 but at a higher risk of residual nodal disease following BCS and positive SLNB may benefit from ALND + BRT, rather than BRT alone...
  16. doi request reprint Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management
    Laura E G Warren
    Harvard Radiation Oncology Program, Boston, MA, USA
    Ann Surg Oncol 22:2483-91. 2015
    ..Inflammatory breast cancer (IBC) is a rare and aggressive subtype. This study analyzes the patterns of failure in patients with IBC treated at our institution...
  17. doi request reprint Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy
    Andrea L Russo
    Harvard Radiation Oncology Program, Boston, MA 02215, USA
    Breast Cancer Res Treat 140:353-61. 2013
    ..Additional studies are needed to confirm this finding. ..
  18. doi request reprint Surgical margins and the risk of local-regional recurrence after mastectomy without radiation therapy
    Stephanie K Childs
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Int J Radiat Oncol Biol Phys 84:1133-8. 2012
    ..We sought to clarify the influence of the mastectomy margin on the risk of LRR...
  19. doi request reprint Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review
    Ronald C Chen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:4981-9. 2008
    ..However, even in patients with visualized primary IMN drainage, the potential benefit of treatment should be balanced against the risk of added morbidity...
  20. doi request reprint Automation of clip localization in Digital Tomosynthesis for setup of breast cancer patients
    Sook Kien Ng
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Phys Med 29:75-82. 2013
    ..3mm for 60° and 3.3mm for 40° DTS. When incorporated in clinical software, this algorithm helps to facilitate fast and accurate setup evaluation with minimal dose delivered to patients...
  21. doi request reprint Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ
    Lia M Halasz
    Harvard Radiation Oncology Program, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 82:e581-6. 2012
    ..We sought to determine the following: LR rates with this more modern approach; the relation between LR and HER-2 status; and clinical and pathologic factors associated with HER-2(+) DCIS...
  22. ncbi request reprint Clinical application of varian OBI CBCT system and dose reduction techniques in breast cancer patients setup
    Stefan Ueltzhöffer
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Med Phys 37:2985-98. 2010
    ..To characterize the standard modes of Varian on board imaging (OBI) v1.4 system and identify techniques to further optimize imaging parameters, in particular, for breast treatment setup...
  23. ncbi request reprint Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 64:496-504. 2006
    ..To evaluate the safety and feasibility of concurrent radiation therapy and paclitaxel-based adjuvant chemotherapy, given either weekly or every 3 weeks, after adjuvant doxorubicin and cyclophosphamide (AC)...
  24. ncbi request reprint A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer
    May Lim
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 65:1149-54. 2006
    ..Whether a subset of women can achieve local control without RT is unknown. In 1986, we initiated a prospective one-arm trial of BCS alone for highly selected breast-cancer patients. This report updates those results...
  25. ncbi request reprint Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy
    Lior Z Braunstein
    Harvard Radiation Oncology Program, Boston, MA, USA
    Breast Cancer Res Treat . 2016
    ..Advances in breast-conserving therapy (BCT) have yielded local control rates comparable or superior to those of mastectomy. In this study, we sought to identify contemporary risk factors associated with local recurrence (LR) following BCT...
  26. doi request reprint Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer?
    Jennifer R Bellon
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:3916-20. 2012
    ..The margins are negative, as are all 11 axillary lymph nodes. Her pathologic response to neoadjuvant treatment is judged Miller-Payne grade 4. She is referred for consideration of postmastectomy irradiation...
  27. ncbi request reprint Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity
    Daniel M Landis
    Joint Center for Radiation Therapy Residency Training Program, Harvard Medical School, Brigham and Women s Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 67:1299-308. 2007
    ..We examined the interobserver variability in delineation of the lumpectomy cavity among four academic radiation oncologists who specialize in the treatment of breast cancer...
  28. pmc Partial breast irradiation versus whole breast radiotherapy for early-stage breast cancer: a decision analysis
    David J Sher
    Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 70:469-76. 2008
    ..To compare the quality-adjusted life expectancy between women treated with partial breast irradiation (PBI) vs. whole breast radiotherapy (WBRT) for estrogen receptor-positive early-stage breast cancer...
  29. doi request reprint A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
    Nancy U Lin
    Harvard Medical School, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 142:405-14. 2013
    ..Given the high ORR, concurrent lapatinib-WBRT could still be considered for future study with careful safety monitoring. ..
  30. doi request reprint Optimal parameters for clinical implementation of breast cancer patient setup using Varian DTS software
    Sook Kien Ng
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Faber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Appl Clin Med Phys 13:3752. 2012
    ..The performance of Varian DTS software was found suitable for the accurate setup of breast cancer patients. Optimal data acquisition and registration parameters were determined...
  31. doi request reprint Inflammatory breast cancer and development of brain metastases: risk factors and outcomes
    Laura E G Warren
    Harvard Radiation Oncology Program, Boston, MA, USA
    Breast Cancer Res Treat 151:225-32. 2015
    ..33; 95 % CI, 1.11-4.89; P = 0.03). The incidence of brain metastases is high in women with IBC. Particularly for patients with extracranial distant metastases, routine screening with magnetic resonance imaging should be considered. ..
  32. pmc Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343
    Kevin S Hughes
    Harvard Medical School, Boston, MA, USA
    J Clin Oncol 31:2382-7. 2013
    ..To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer...
  33. ncbi request reprint Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?
    Davendra Segara
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Surg Oncol 96:474-80. 2007
    ..The purpose of this study is to review imaging studies performed in patients who received preoperative chemotherapy prior to surgery and determine whether MRI, ultrasound (US) or physical exam best predicted final pathologic tumor size...
  34. doi request reprint Mammographic appearance following accelerated partial breast irradiation by using MammoSite brachytherapy
    Haitham M Ahmed
    Department of Radiation Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Radiology 255:362-8. 2010
    ..To describe a single institution's experience with mammographic appearance in low-risk patients with early stage breast cancer who have received accelerated partial breast irradiation (APBI) by using MammoSite balloon brachytherapy...
  35. ncbi request reprint Radiation therapy for breast cancer
    Jennifer R Bellon
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Hematol Oncol Clin North Am 20:239-57, vii. 2006
    ..This article summarizes the adjuvant role of RT after mastectomy and lumpectomy, as well as the rationale and techniques for partial-breast irradiation...
  36. ncbi request reprint CT computer-optimized high-dose-rate brachytherapy with surface applicator technique for scar boost radiation after breast reconstruction surgery
    Alexandra J Stewart
    Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Brachytherapy 4:224-9. 2005
    ..Two cases, one with a saline implant and one with a transverse rectus abdominis musculocutaneous flap reconstruction, illustrate the method and advantages of HDR optimization of surface applicators...
  37. doi request reprint Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ
    Ann Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 8:275-80. 2008
    ..We sought in a longitudinal cohort study of women with DCIS to assess the attitudes and management approaches toward DCIS among physicians who provide care to women...
  38. ncbi request reprint Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer
    Laura E G Warren
    Harvard Radiation Oncology Program, Boston, MA, USA
    Ann Surg Oncol 23:3870-3879. 2016
    ..However, the relationship between BMI and locoregional recurrence (LRR) has been less well studied and was therefore the subject of this investigation...
  39. doi request reprint Management of the Regional Lymph Nodes in Early-Stage Breast Cancer
    Julia S Wong
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA
    Semin Radiat Oncol 26:37-44. 2016
    ..We review the controversies in regional nodal management, the benefits of current treatment paradigms, the balance between less surgery and more radiation, and the potential tradeoffs vs toxicity...
  40. doi request reprint What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach
    Eren D Yeh
    From the Division of Breast Imaging, Department of Radiology, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, RA Bldg, RA 014, Boston, MA 02115 E D Y, R L B, D G S, C S G and Department of Imaging H A J, A D V d A, Department of Radiation Oncology J R B, Department of Surgery F N, Department of Breast Oncology B O, and Inflammatory Breast Cancer Program E D Y, H A J, J R B, F N, J H B, B O, Dana Farber Cancer Institute, Boston, Mass
    Radiographics 33:2003-17. 2013
    ..Imaging is vital to diagnosis and treatment planning for patients with IBC, and radiologists are an integral part of the multidisciplinary patient care team. ..
  41. doi request reprint Optimal gantry angles and field sizes in kilovoltage cone-beam tomosynthesis for set-up of women with breast cancer undergoing radiotherapy treatment
    Yulia Lyatskaya
    Department of Radiation Oncology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Radiother Oncol 93:633-8. 2009
    ..Maximum required jaw openings were 20 x 14 cm(2). Recommendations are provided for clinical implementation of CB-TS imaging for breast cancer patients...
  42. pmc Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A
    WILLIAM M SIKOV
    William M Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI Donald A Berry, University of Texas MD Anderson Cancer Center, Houston, TX Charles M Perou and Lisa A Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill Constance T Cirrincione, Alliance Statistical Center, Durham Charles S Kuzma, Southeast Cancer Control Consortium, Winston Salem, NC Baljit Singh, New York University Medical Center Elisa R Port, Mount Sinai Medical Center Clifford A Hudis, Memorial Sloan Kettering Cancer Center, New York, NY Sara M Tolaney, Mehra Golshan, Jennifer R Bellon, and Eric P Winer, Dana Farber Cancer Institute, Boston, MA Timothy J Pluard, Washington University St Louis Medical Center, St Louis, MO George Somlo, City of Hope Comprehensive Cancer Center, Duarte Deborah Collyar, Patient Advocates In Research, Danville, CA and Olwen M Hahn, University of Chicago Medical Center, Chicago, IL
    J Clin Oncol 33:13-21. 2015
    ..CALGB 40603 (Alliance), a 2 × 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevacizumab...
  43. ncbi request reprint CNS metastases in breast cancer
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 22:3608-17. 2004
    ..Studies specifically targeted toward this group of patients are needed...
  44. doi request reprint Case records of the Massachusetts General Hospital. Case 30-2008. A 47-year-old woman with a mass in the breast and a solitary lesion in the spine
    William J Gradishar
    Department of Medicine, Northwestern University, and the Feinberg School of Medicine, Chicago, USA
    N Engl J Med 359:1382-91. 2008
  45. ncbi request reprint Chemotherapy and radiation therapy for breast cancer: what is the optimal sequence?
    Jennifer R Bellon
    J Clin Oncol 23:5-7. 2005